DGAP-News

SYGNIS AG signs initial distribution agreement for the Asian market for the TruePrime(TM) product family with Japanese Funakoshi Co. Ltd.

DGAP-News: SYGNIS AG / Key word(s): Agreement
SYGNIS AG signs initial distribution agreement for the Asian market
for the TruePrime(TM) product family with Japanese Funakoshi Co. Ltd.

04.03.2015 / 08:00

---------------------------------------------------------------------

Press Release

SYGNIS AG signs initial distribution agreement for the Asian market for the
TruePrime(TM) product family with Japanese Funakoshi Co. Ltd.

- Distribution agreement for Japan, the second largest life science
market in the world today

- FUNAKOSHI is a leading Japanese life science distributor with focus on
molecular biology, protein research, cell biology and diagnostics

- TruePrime(TM) family for whole genome amplification without the need of
synthetic random primers on stock and ready for distribution in Japan

Madrid, Spain and Heidelberg, Germany, March 04, 2015 - SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that
it has signed an non-exclusive distribution agreement for SYGNIS'
TruePrime(TM) family with FUNAKOSHI Co. Ltd. for the Japanese market.

With this agreement, SYGNIS grants FUNAKOSHI the non-exclusive rights to
promote, market and sell all existing as well as future products for DNA
and RNA amplification from smallest amounts of samples down to single cells
for applications such as next generation sequencing (NGS) in Japan. SYGNIS'
TruePrime(TM) product family is based on SYGNIS' revolutionary novel
multiple displacement amplification (MDA) technology for the amplification
of various DNA or RNA species for a multitude of applications.

As a leading solution provider, FUNAKOSHI is offering a broad portfolio of
quality research reagents as well as high-tech instruments in the wide
fields of molecular biology, protein research, cell biology and diagnostics
to customers all over Japan.

"We are very pleased about this distribution agreement for our proprietary
product portfolio with FUNAKOSHI, an important gatekeeper in Japan, the
second largest life science market in the world today. With its wide
customer network focused on molecular biology and diagnostics, FUNAKOSHI is
best positioned to leverage the benefits of our existing as well as future
products to customers in molecular biology especially in the fast growing
field of NGS in Japan," Pilar de la Huerta, CEO and CFO of SYGNIS
commented. "After we successfully signed distributions agreements for North